Skip to main content

This site is intended for US healthcare professionals only.

TAKE A GUIDED TOUR TO DISCOVER WHAT THIS NON-HORMONAL CONTRACEPTIVE OPTION HAS TO OFFER.    START NOW!
Toggle X
phexxi-non-hormonal-birth-control-rep-icon

Contact an Evofem Regional Business Manager

All fields required.

Contact preference:
Best time to reach:
Are you:
Form Submitted Thank You
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
NEW For prescription only


A non-hormonal contraceptive used in the moment

pHinally! A first-in-class vaginal pH modulator (VPM)– Phexxi is a bioadhesive gel that maintains the acidic pH of the vagina to prevent pregnancy1-5

Many women have unmet needs when it comes to birth control1

They are looking for an option that:

  • Is non-hormonal
  • Is woman controlled and used in the moment
  • Is easy to use and begins working immediately
In Fact...

There are

21 Million
Women

at risk for pregnancy who are
NOT using hormonal contraception2

Meet the woman who is
beyond hormones

There may be women in your practice who...

  • Prefer non-hormonal contraception because of unwanted side effects experienced with hormones
  • Currently use condoms or withdrawal method
  • Want an easily reversible method
  • Are likely to research contraceptive options and prefer methods that fit their healthy lifestyles
Informed choice is an important contributor to the successful use of any contraceptive method, including ease of use, convenience, side effects, and efficacy1,2
 

A non-hormonal contraceptive that maintains vaginal pH to prevent pregnancy1

How It Works
By maintaining the vagina's acidic pH level, which creates an inhospitable environment for sperm2-4
By creating a bioadhesive, viscous layer of gel over the vaginal and cervical surfaces, which allows Phexxi to remain in place and maintain an acidic environment within the vagina2-4

AMPOWER: A Phase 3 Clinical Trial1

Trial Design

  • Single-arm, open-label trial
  • 112 sites
  • 1384 women aged 18 to 35
  • Primary endpoint: 7-cycle cumulative pregnancy rate as calculated by the Kaplan-Meier method

AMPOWER: A Phase 3 Clinical Trial

Phexxi met the FDA-prescribed primary endpoint for pregnancy prevention over 7 cycles of usea

  • Over 32,000 acts of intercourse reported during the study1
The 7-cycle cumulative pregnancy rate (primary efficacy outcome) was 13.7% (95% CI: 10.0%, 17.5%),2 which corresponds toa:
A secondary efficacy analysis, the 7-cycle cumulative pregnancy rate for perfect use, resulted in a pregnancy rate of 6.7% (95% CI: 4.61%, 8.73%),3 which corresponds toa:

Safety profilea

The most common adverse reactions in clinical studies (≥10%) were1:

  • Vulvovaginal burning sensation (18.0%)
  • Vulvovaginal pruritus (14.5%)

The majority of adverse reactions were mild and few led to discontinuation1

  • 1.6% of patients discontinued due to adverse reactions
  • Two subjects discontinued due to male partner symptoms. 9.8% of male partners reported local discomfortb

Warnings and Precautions1

  • There were few cases (0.36%) of cystitis, pyelonephritis and other upper urinary tract infections. Of these, one case of pyelonephritis was considered serious and required hospitalization

Phexxi...

  • Should be avoided in women who have had recurrent urinary tract infections or abnormalities1
  • Should be avoided if the woman or her partner is allergic to any of the ingredients in Phexxi1
  • May be used with other contraceptives, including latex, polyurethane, and polyisoprene condoms; and vaginal diaphragms. Avoid Phexxi use with vaginal rings1
  • Is not expected to lead to safety concerns from systemic exposure to ingredients following vaginal exposurec
  • aThe safety of Phexxi has been evaluated in 2 clinical trials in 2804 subjects.
  • bIn the AMPOWER study.
  • cPharmacokinetic studies have not been performed.

This is not an exhaustive list of all adverse reactions. See full Prescribing Information to learn more.

Quick and easy to use1

  • Phexxi is effective immediately upon administration2
Administer an additional dose of Phexxi™ if intercourse does not occur within 1 hour of administration or if another act of intercourse occurs within 1 hour.2

pHinally! An FDA-approved, non-hormonal contraceptive vaginal gel for women who are seeking non-hormonal contraception

  • Woman controlled and used in the moment
  • Easy to use and begins working immediately
  • Under the Affordable Care Act, Phexxi may be available for $0 co-pay, co-insurance, or deductible
Consider Phexxi for pregnancy prevention today!

HAVE QUESTIONS? LEARN MORE HERE

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females of reproductive potential with history of recurrent urinary tract infection or urinary tract abnormalities.

ADVERSE REACTIONS

Most common adverse reactions were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain.

Patients should be counseled on the following:

  • To contact and consult with their healthcare provider for severe or prolonged genital irritation or experiencing urinary tract symptoms.
  • To discontinue Phexxi if they develop a local hypersensitivity reaction.
  • That Phexxi does not protect against HIV infection or other sexually transmitted infections.

To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or you may contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS AND USAGE

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

Please see full Prescribing Information for Phexxi.

Expand ISI

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females of reproductive potential with history of recurrent urinary tract infection or urinary tract abnormalities.